Akebia Therapeutics Company Profile (NASDAQ:AKBA)

About Akebia Therapeutics

Akebia Therapeutics logoAkebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company's segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AKBA
  • CUSIP:
Key Metrics:
  • Previous Close: $9.93
  • 50 Day Moving Average: $9.95
  • 200 Day Moving Average: $8.94
  • 52-Week Range: $18,300,000.00 - $7.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.75
  • P/E Growth: 0.00
  • Market Cap: $181.90M
  • Outstanding Shares: 18,300,000
  • Beta: 1.07
Profitability:
  • Return on Equity: -88.40%
  • Return on Assets: -64.59%
Debt:
  • Current Ratio: 6.32%
  • Quick Ratio: 6.32%
Additional Links:
Companies Related to Akebia Therapeutics:

Analyst Ratings

Consensus Ratings for Akebia Therapeutics (NASDAQ:AKBA) (?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $16.29 (63.84% upside)

Analysts' Ratings History for Akebia Therapeutics (NASDAQ:AKBA)
Show:
DateFirmActionRatingPrice TargetDetails
2/14/2017AegisReiterated RatingBuy$21.00View Rating Details
12/27/2016HC WainwrightBoost Price TargetBuy$17.00 -> $18.00View Rating Details
12/20/2016Needham & Company LLCSet Price TargetBuy$14.00View Rating Details
12/20/2016JMP SecuritiesBoost Price TargetOutperform$16.00 -> $19.00View Rating Details
9/29/2016Brean CapitalInitiated CoverageBuy$18.00View Rating Details
8/9/2016Credit Suisse GroupReiterated RatingHold$8.00View Rating Details
5/8/2016Morgan StanleyReiterated RatingBuyView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$24.00 -> $16.00View Rating Details
5/12/2015NomuraReiterated RatingBuy$37.00 -> $27.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/7/2016Q3($1.09)($0.96)ViewN/AView Earnings Details
3/14/2016Q415($0.28)($0.66)$11.60 millionViewListenView Earnings Details
11/9/2015Q3($0.52)($0.68)ViewN/AView Earnings Details
8/11/2015Q215($0.51)($0.40)ViewN/AView Earnings Details
5/11/2015($0.57)($0.53)ViewN/AView Earnings Details
3/4/2015Q414($0.66)($0.52)ViewN/AView Earnings Details
11/10/2014Q314($0.45)($0.47)ViewN/AView Earnings Details
8/11/2014($0.34)($0.39)ViewN/AView Earnings Details
5/12/2014($0.38)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Akebia Therapeutics (NASDAQ:AKBA)
Current Year EPS Consensus Estimate: $-2.03 EPS
Next Year EPS Consensus Estimate: $-1.73 EPS

Dividends

Dividend History for Akebia Therapeutics (NASDAQ:AKBA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Akebia Therapeutics (NASDAQ:AKBA)
Insider Ownership Percentage: 7.95%
Institutional Ownership Percentage: 49.50%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Duane NashDirectorSell1,980$10.46$20,710.80View SEC Filing  
1/1/2017Nicole R. HadasSVPSell1,810$10.49$18,986.90View SEC Filing  
7/6/2016Duane NashDirectorSell1,980$7.48$14,810.40View SEC Filing  
7/5/2016Nicole R. HadasSVPSell1,557$7.47$11,630.79View SEC Filing  
4/4/2016Michel DahanSVPSell1,401$9.41$13,183.41View SEC Filing  
10/2/2015Nicole R HadasSVPSell1,484$8.67$12,866.28View SEC Filing  
7/2/2015Nicole R HadasSVPSell1,484$9.54$14,157.36View SEC Filing  
4/22/2015Muneer A SatterDirectorBuy420,000$8.25$3,465,000.00View SEC Filing  
4/2/2015Nicole R HadasSVPSell1,483$9.09$13,480.47View SEC Filing  
1/2/2015Nicole R HadasVPSell1,715$11.46$19,653.90View SEC Filing  
12/29/2014John P ButlerCEOBuy1,000$11.57$11,570.00View SEC Filing  
12/26/2014Duane NashDirectorSell11,933$11.23$134,007.59View SEC Filing  
12/22/2014John P ButlerCEOBuy1,000$11.92$11,920.00View SEC Filing  
12/15/2014John P ButlerCEOBuy1,000$11.34$11,340.00View SEC Filing  
12/2/2014Ronald C Renaud JrDirectorBuy5,000$11.92$59,600.00View SEC Filing  
11/26/2014Jason AmelloCFOBuy1,000$13.22$13,220.00View SEC Filing  
11/25/2014Muneer A SatterDirectorBuy5,000$13.18$65,900.00View SEC Filing  
11/24/2014Muneer A SatterDirectorBuy5,000$13.88$69,400.00View SEC Filing  
11/21/2014Muneer A SatterDirectorBuy5,000$14.73$73,650.00View SEC Filing  
11/20/2014Muneer A SatterDirectorBuy5,000$14.70$73,500.00View SEC Filing  
11/19/2014Muneer A SatterDirectorBuy5,000$14.85$74,250.00View SEC Filing  
11/18/2014Muneer A SatterDirectorBuy5,000$13.84$69,200.00View SEC Filing  
11/17/2014Muneer A SatterDirectorBuy5,000$12.94$64,700.00View SEC Filing  
11/14/2014Muneer A SatterDirectorBuy5,000$11.91$59,550.00View SEC Filing  
11/13/2014Muneer A SatterDirectorBuy5,000$11.56$57,800.00View SEC Filing  
11/12/2014John P ButlerCEOBuy1,000$10.31$10,310.00View SEC Filing  
11/12/2014Muneer A SatterDirectorBuy5,000$11.90$59,500.00View SEC Filing  
3/25/2014A/S NovoInsiderBuy182,590$17.00$3,104,030.00View SEC Filing  
3/25/2014Jason AmelloCFOBuy4,000$17.00$68,000.00View SEC Filing  
3/25/2014John P ButlerCEOBuy13,850$17.00$235,450.00View SEC Filing  
3/25/2014Muneer A SatterDirectorBuy91,295$17.00$1,552,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Akebia Therapeutics (NASDAQ:AKBA)
DateHeadline
News IconStock Levels in Review for Akebia Therapeutics Inc (AKBA) - Providence Standard (NASDAQ:AKBA)
providencestandard.com - February 27 at 6:46 AM
News IconShares in Review: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - BVN (NASDAQ:AKBA)
bvnewsjournal.com - February 23 at 3:27 PM
News IconAre Analysts Optimistic About Where Akebia Therapeutics, Inc. (NASDAQ:AKBA) is Heading? - Winfield Review (NASDAQ:AKBA)
winfieldreview.com - February 22 at 8:29 PM
News IconWhat are Analysts Expecting for Akebia Therapeutics, Inc. (NASDAQ ... - Aiken Advocate (NASDAQ:AKBA)
aikenadvocate.com - February 22 at 3:27 PM
News IconFocusing the Lens on Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Midway Monitor (NASDAQ:AKBA)
midwaymonitor.com - February 22 at 3:27 PM
News IconAkebia Therapeutics Inc AKBA Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:AKBA)
www.bioportfolio.com - February 22 at 11:37 AM
News IconStock Watch Near-Term: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Rockville Register (NASDAQ:AKBA)
rockvilleregister.com - February 21 at 3:42 PM
investornewswire.com logoStrong Sell Recommendations Of Akebia Therapeutics, Inc. (NASDAQ:AKBA) At 0 - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - February 21 at 6:53 AM
News IconAnalysts Peer Into Their Crystal Balls For Akebia Therapeutics, Inc. (NASDAQ:AKBA): Where Is It headed? - Winfield Review (NASDAQ:AKBA)
winfieldreview.com - February 21 at 6:53 AM
News IconKeeping Tabs on the Technicals For Akebia Therapeutics, Inc ... - BVN (NASDAQ:AKBA)
bvnewsjournal.com - February 17 at 6:39 PM
News IconTrading Watch: Checking in on Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Searcy News (NASDAQ:AKBA)
searcysentinel.com - February 16 at 3:29 PM
marketexclusive.com logoAnalyst Activity – Aegis Reiterates Buy on Akebia Therapeutics (NASDAQ:AKBA) - Market Exclusive (NASDAQ:AKBA)
marketexclusive.com - February 16 at 7:37 AM
finance.yahoo.com logoKalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6% (NASDAQ:AKBA)
finance.yahoo.com - February 16 at 7:37 AM
seekingalpha.com logoAkebia Therapeutics (AKBA) Presents at 19th Annual BIO CEO & Investor Conference (NASDAQ:AKBA)
seekingalpha.com - February 15 at 1:46 AM
us.rd.yahoo.com logo7:03 am Akebia Therapeutics enters into exclusive agreement with Johnson & Johnson (JNJ (NASDAQ:AKBA)
us.rd.yahoo.com - February 15 at 1:46 AM
biz.yahoo.com logoAKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ (NASDAQ:AKBA)
us.rd.yahoo.com - February 15 at 1:46 AM
News IconAkebia Therapeutics, Inc. (AKBA) stock moves up, “Buy” rating reaffirmed by Aegis Analysts - The Ledger Gazette (NASDAQ:AKBA)
ledgergazette.com - February 14 at 3:43 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics (NASDAQ:AKBA)
finance.yahoo.com - February 14 at 3:43 PM
investornewswire.com logoAkebia Therapeutics, Inc. (NASDAQ:AKBA) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - February 13 at 3:53 PM
News IconTrading Levels in Focus: Akebia Therapeutics Inc. (AKBA) - Sherwood Daily (NASDAQ:AKBA)
sherwooddaily.com - February 11 at 3:26 PM
News IconStock Levels in Review for Akebia Therapeutics Inc. (AKBA) - Providence Standard (NASDAQ:AKBA)
providencestandard.com - February 8 at 3:37 PM
reuters.com logoBiotech employee arrested, accused by US of insider trading - Reuters (NASDAQ:AKBA)
www.reuters.com - February 7 at 3:53 PM
News IconTrading Radar: Zooming in on Shares of Akebia Therapeutics Inc. (AKBA) - Sherwood Daily (NASDAQ:AKBA)
sherwooddaily.com - February 3 at 3:33 PM
News IconTrading Radar: Zooming in on Shares of Akebia Therapeutics Inc. (AKBA) - Sherwood Daily (NASDAQ:AKBA)
sherwooddaily.com - February 3 at 3:33 PM
finance.yahoo.com logoAkebia to Present at the 19th BIO CEO & Investor Conference (NASDAQ:AKBA)
finance.yahoo.com - February 3 at 3:33 PM
finance.yahoo.com logoConcordia International (CXRX) Looks Good: Stock Jumps 11.4% (NASDAQ:AKBA)
finance.yahoo.com - February 3 at 3:33 PM
News IconChecking Indicator Levels for Akebia Therapeutics Inc. (AKBA) - Sherwood Daily (NASDAQ:AKBA)
sherwooddaily.com - February 1 at 8:35 PM
News IconAnalysts Take the Wheel on Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares and Where They Might Be Headed - Aiken Advocate (NASDAQ:AKBA)
aikenadvocate.com - February 1 at 3:33 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Akebia Therapeutics, Inc. (NASDAQ:AKBA)? - Wall Street Beacon (NASDAQ:AKBA)
wsbeacon.com - February 1 at 3:33 PM
News IconTrading Scope: Checking on Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - The Tribune (NASDAQ:AKBA)
lakecitytribune.com - January 30 at 3:37 PM
News IconVolatility Numbers in View for Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Gilbert Daily (NASDAQ:AKBA)
gilbertdaily.com - January 29 at 8:27 PM
News IconTrading Focus: Eye on Shares of Akebia Therapeutics Inc. (AKBA) - Rives Journal (NASDAQ:AKBA)
rivesjournal.com - January 28 at 3:27 PM
News IconStock Tracker: Looking at the Numbers for Akebia Therapeutics, Inc. (NASDAQ:AKBA) - The Tribune (NASDAQ:AKBA)
lakecitytribune.com - January 27 at 3:34 PM
News IconTrading Spotlight: Zooming in on Shares of Akebia Therapeutics Inc. (AKBA) - Sherwood Daily (NASDAQ:AKBA)
sherwooddaily.com - January 26 at 8:40 PM
News IconAnalysts Take: Akebia Therapeutics, Inc. (NASDAQ:AKBA) Projected ... - Aiken Advocate (NASDAQ:AKBA)
aikenadvocate.com - January 25 at 8:33 PM
News IconEarnings in Full Force, Analysts Take Aim at Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Wall Street Beacon (NASDAQ:AKBA)
wsbeacon.com - January 25 at 3:31 PM
News IconTechnical Indicator Review on Shares of Akebia Therapeutics Inc. (AKBA) - Sherwood Daily (NASDAQ:AKBA)
sherwooddaily.com - January 25 at 1:55 AM
News IconMoody Stock Sees Increased Volatility Levels in Session: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Wall Street Beacon (NASDAQ:AKBA)
wsbeacon.com - January 25 at 1:55 AM
zacks.com logoNew Strong Buy Stocks for January 24th (NASDAQ:AKBA)
www.zacks.com - January 24 at 3:47 PM
News IconValue Composite Score Update on Akebia Therapeutics, Inc. (NASDAQ:AKBA) - The Tribune (NASDAQ:AKBA)
lakecitytribune.com - January 23 at 3:28 PM
News IconStock Backsliding Ahead of the Bell: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Aiken Advocate (NASDAQ:AKBA)
aikenadvocate.com - January 23 at 3:28 PM
News IconInvestor Focus on Shares of Akebia Therapeutics Inc. (AKBA) - Sherwood Daily (NASDAQ:AKBA)
sherwooddaily.com - January 22 at 3:26 PM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Wall Street Beacon (NASDAQ:AKBA)
wsbeacon.com - January 22 at 8:19 AM
News IconAkebia Therapeutics Inc AKBA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:AKBA)
www.bioportfolio.com - January 21 at 1:49 AM
News IconLooking at Moving Averages for Akebia Therapeutics Inc. (AKBA) - Rives Journal (NASDAQ:AKBA)
rivesjournal.com - January 20 at 8:47 PM
News IconStock Overview: Moving Average Check on Akebia Therapeutics Inc. (AKBA) - Sherwood Daily (NASDAQ:AKBA)
sherwooddaily.com - January 19 at 3:47 PM
finance.yahoo.com logoWhy Akebia Therapeutics (AKBA) Could Be Positioned for a Surge (NASDAQ:AKBA)
finance.yahoo.com - January 18 at 3:58 PM
finance.yahoo.com logoMoving Average Crossover Alert: Akebia (AKBA) (NASDAQ:AKBA)
finance.yahoo.com - January 11 at 3:43 PM
openpr.com logoAkebia Therapeutics Inc (NASDAQ:AKBA) Investor Lawsuit alleges Misleading Statements (NASDAQ:AKBA)
www.openpr.com - January 10 at 3:28 PM
News IconBetter Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc ... - Madison.com (NASDAQ:AKBA)
host.madison.com - January 5 at 3:39 PM

Social

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Where is Akebia Therapeutics' stock going? Where will Akebia Therapeutics' stock price be in 2017?

8 brokers have issued 12-month price targets for Akebia Therapeutics' shares. Their predictions range from $8.00 to $21.00. On average, they expect Akebia Therapeutics' stock price to reach $16.29 in the next twelve months.

When will Akebia Therapeutics announce their earnings?

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

What are analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:

  • Aegis analysts commented, "Akebia announced that it had entered into a research and license agreement with Janssen Pharmaceuticals on February 9, 2017. The agreement grants Akebia an exclusive license for potential development and commercialization of hypoxia-inducible factor (HIF) prolyl hydroxylase-targeted compounds' In accordance with the agreement Akebia will pay Janssen an upfront cash payment of $1 mil within 30 days of execution of the agreement. Janssen is also eligible to receive up to an aggregate of $16.5 mil in specified development milestones on a product-byproduct basis. The agreement also specifies that Janssen is eligible to receive up to $215 mil in specified commercial milestones, in addition to tiered, escalating royalties in the range of low to mid-single digits as a percentage of net sales on a product-by-product basis." (2/14/2017)
  • According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (1/11/2017)

  • Brean Capital analysts commented, "We like Akebia's asset, vadadustat, which is a new MOA for treating anemia. If successfully developed, it could change the standard of care," analyst Difei Yang wrote in a note.Related Link: Sarepta Dosing First Patients In Phase 3 Trial Of Duchenne Muscular Dystrophy Drug"International partnerships aside, Akebia will commercialize vadadustat on its own in the US and we project sales to be around $515 mil in 2022, with sales for ND-CKD indication alone," (9/29/2016)

  • HC Wainwright analysts commented, "Trevena announced this morning that the Phase 2b trial of TRV027 in Acute Heart Failure (BLAST-AHF) failed to meet all primary and secondary endpoints. Investor expectations for a successful outcome were relatively low, especially given the historical challenges w/ developing a drug in this indication. We had a modest positive bias given prior preclinical and clinical data. We have removed TRV027 from our model and are lowering our price target to $11 (was $14; 25x 2021 EPS estimate discounted 25% annually). We do not believe the negative TRV027 outcome has an impact on other programs in development at the company. The stock is still undervalued in our opinion, especially given strength of oliceridine pain program and we reiterate BUY." (5/16/2016)

Who owns Akebia Therapeutics stock?

Akebia Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (5.09%), Acuta Capital Partners LLC (3.82%), Marshall Wace LLP (3.76%), Perceptive Advisors LLC (2.94%), State Street Corp (2.90%) and City Financial Investment Co Ltd (1.75%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas.

Who sold Akebia Therapeutics stock? Who is selling Akebia Therapeutics stock?

Akebia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Ellington Management Group LLC and Acuta Capital Partners LLC. Company insiders that have sold Akebia Therapeutics stock in the last year include Duane Nash, Michel Dahan and Nicole R Hadas.

Who bought Akebia Therapeutics stock? Who is buying Akebia Therapeutics stock?

Akebia Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, City Financial Investment Co Ltd, Marshall Wace LLP, Renaissance Technologies LLC, Trexquant Investment LP, State Street Corp, Dynamic Technology Lab Private Ltd and Dimensional Fund Advisors LP.

How do I buy Akebia Therapeutics stock?

Shares of Akebia Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Akebia Therapeutics stock cost?

One share of Akebia Therapeutics stock can currently be purchased for approximately $9.94.

Akebia Therapeutics (NASDAQ:AKBA) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Earnings History Chart

Earnings by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Dividend History Chart

Dividend Payments by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Last Updated on 2/27/2017 by MarketBeat.com Staff